[Skip to Content]

macular oedema

NICE Macular Oedema (Branch Retinal Vein Occlusion) Final Technology Appraisal

Response to NICE announcing their positive final guidance for Eylea® for the treatment of adult patients with visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO) The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea (aflibercept) as a first-line treatment option for patients with visual

Response to NICE announcing their positive draft guidance for Eylea® for the treatment of macular oedema secondary to CRVO

College Statement The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea® (aflibercept) as a treatment option for visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). We hope that this decision will help the clinical commissioning groups to support the rapid implementation of the final